Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $240,000 — Rift Valley fever virus (RVFV), a bunyavirus, is transmitted by mosquitoes and has caused large outbreaks among humans and ruminants in many countries in Africa and the Arabian Peninsula. RVFV outbreaks in the U.S. are quite possible and would cause serious public health, agricultural, and economic …
Kristina M. Adams Waldorf · UNIVERSITY OF WASHINGTON · 2024 · $843,733 — Project Summary Pregnant women are highly vulnerable to influenza A virus (IAV) and are at increased risk for maternal death, preterm birth and stillbirth. Universal influenza vaccines (UFV) are thought to be possible if conserved regions of influenza virus are targeted and appropriate immune respon…
Amit Kapoor · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2024 · $614,828 — Abstract Although direct acting antivirals can cure Hepatitis C virus (HCV) infection, a vaccine is necessary to stop new infections, and to prevent re-infections in the cured individuals. Studies in humans and chimpanzees suggest that both T cells and neutralizing antibodies (nAb) can play an impor…
STEVEN GREGORY REED · HDT BIO CORPORATION · 2024 · $543,301 — PROJECT SUMMARY/ABSTRACT Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obst…
Sujan Shresta · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $721,849 — ABSTRACT The long-term goal of this project is to develop a dengue-Zika vaccine that provides protection against the four serotypes of dengue (DENV1-4) and Zika (ZIKV) viruses with maximal safety and efficacy. To date, flavivirus vaccine development has focused on the induction of neutralizing antib…
Styliani Karanika · JOHNS HOPKINS UNIVERSITY · 2024 · $200,880 — PROJECT SUMMARY Host status plays a major role in tuberculosis (TB) disease outcomes, with many efforts to develop host-directed therapies to boost immune response. It is unknown how these strategies will perform in people living with HIV/AIDS (PLWHA) who are at increased risk of adverse TB treatmen…
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2024 · $653,018 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…
SAMUEL SINGER · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $2,375,406 — ABSTRACT The long-term goal of the SPORE in Soft Tissue Sarcoma is to reduce the morbidity and mortality from soft tissue sarcoma by developing therapies targeted to specific molecular, genetic, epigenetic, and signaling pathway alterations or specific sarcoma type and subtype. To pursue this, we wi…
SANDHYA VASAN · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2024 · $880,838 — Project Summary/Abstract An HIV-1 (HIV) vaccine capable of eliciting broad and potent neutralizing antibody (Ab) response to HIV envelope (Env) remains elusive. HIV has a high mutation rate, Env is highly glycosylated as well as conformationally dynamic and, well-characterized broadly neutralizing r…
MING LUO · GEORGIA STATE UNIVERSITY · 2024 · $540,203 — The devastating impact on public health, global economy and social stability incurred by the COVID-19 pandemic in the last two years has highlighted the importance of basic research into zoonotic pathogens. This application describes structural and functional studies into the rodent-borne human path…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $513,877 — ABSTRACT Recent clinical success of mRNA vaccines for COVID-19 has sparked enormous interest in mRNA therapy for a wide range of biomedical applications including protein replacement therapy. However, one unique challenge associated with mRNA therapy is dealing with the transient efficacy due to its…
Denise L. Doolan · UNIVERSITY OF QUEENSLAND · 2024 · $476,538 — PA-19-077 DOOLAN: PROJECT SUMMARY Malaria remains a global public health problem with nearly half of the world's population at risk. An effective malaria vaccine would prevent almost half a million deaths and over 200 million clinical cases each year and help eradicate the disease. The most effectiv…
Yizhou Dong · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $751,497 — PROJECT SUMMARY A vaccine is a promising approach for stopping the spread of HIV infections. Although vaccine regimens in clinical trials show various levels of protection against HIV, there is no effective vaccine available for a large population yet. Preclinical and clinical data demonstrate the i…
Fredrick Heath Damron · WEST VIRGINIA UNIVERSITY · 2024 · $812,208 — PROJECT SUMMARY Pertussis is a respiratory disease caused by the obligate human pathogen Bordetella pertussis. Two generations of pertussis vaccines have been developed and licensed: whole cell pertussis (DTP) and acellular pertussis (DTaP/Tdap). Pertussis was thought to be a disease of the past but…
Christopher S Anderson · UNIVERSITY OF ROCHESTER · 2024 · $101,672 — Respiratory Syncytial Virus (RSV) is the second leading cause of hospitalization in children worldwide and has been increasing appreciated as a cause of hospitalization and death in the elderly. Recent studies have shown that polyvalent vaccine formulations, mixture of antigens derived from distinct…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2024 · $530,230 — PROJECT ABSTRACT RNA therapeutics and their corresponding nanomedicines are poised to rapidly change the landscape of healthcare. To address needs in various diseases, RNA-based technologies must function in vivo with biological interactions at various levels from whole body (systemic biodistributio…
Jie Sun · UNIVERSITY OF VIRGINIA · 2024 · $697,498 — PROJECT SUMMARY/ABSTRACT In the wake of a global pandemic caused by the ancestral strain of SARS-CoV-2, infections with emerging variant strains are an ongoing cause of morbidity and mortality. Robust respiratory mucosal immune responses to SARS-CoV-2 infection and/or vaccination are vital to preven…
qing sun · TEXAS ENGINEERING EXPERIMENT STATION · 2024 · $359,373 — Among all approaches, messenger RNA (mRNA)-based vaccines have emerged as a rapid and versatile candidate to quickly respond to virus pandemics, including coronavirus disease 2019 (COVID-19). But mRNA vaccines face key potential limitations. Researchers have observed that RNA molecules tend to spont…
Michela Locci · UNIVERSITY OF PENNSYLVANIA · 2024 · $668,622 — SUMMARY Messenger RNA (mRNA) vaccines represent a powerful vaccine approach for the induction of protective immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since this vaccine platform was approved for human use in 2020 for the first time, little is known about …
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…